Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol

被引：31
|
作者：
Barnes, Theresa [1 ]
Moots, Robert [1 ]
机构：
[1] Univ Liverpool, Acad Rheumatol, Liverpool L69 3BX, Merseyside, England
来源：
INTERNATIONAL JOURNAL OF NANOMEDICINE | 2007年 / 2卷 / 01期
基金：
英国医学研究理事会;
关键词：
certolizumab pegol; TNF alpha; rheumatoid arthritis; nanomolecule;
D O I：
10.2147/nano.2007.2.1.3
中图分类号：
TB3 [工程材料学];
学科分类号：
0805 ; 080502 ;
摘要：
Anti-TNF alpha therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNF alpha agent, a nanomolecule comprising a humanized Fab' antibody fragment against TNF alpha with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this new molecule, data from trials so far, and its potential place in the market place.
引用
收藏
页码：3 / 7
页数：5
相关论文
共 50 条
  • [21] Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
    Hannech, Emna
    Boussaid, Soumaya
    Rekik, Sonia
    Jemmali, Samia
    Ajlani, Houda
    Cheour, Elhem
    Sahli, Hela
    Elleuch, Mohamed
    CLINICAL CASE REPORTS, 2021, 9 (06):
  • [22] Certolizumab Pegol A Review of Its Use in the Management of Rheumatoid Arthritis
    Deeks, Emma D.
    DRUGS, 2013, 73 (01) : 75 - 97
  • [23] How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol
    Vicenç Torrente-Segarra
    Manuel Fernandez Prada
    Rosa Expósito Moliner
    Noemí Patricia Garrido Puñal
    Amalia Sánchez-Andrade Fernández
    José Ramón Lamua Riazuelo
    Alejandro Olivé
    Juan Víctor Tovar Beltrán
    Rheumatology International, 2019, 39 : 395 - 398
  • [24] Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
    Ruiz Garcia, Vicente
    Jobanputra, Paresh
    Burls, Amanda
    Cabello, Juan B.
    Galvez Munoz, Jose G.
    Saiz Cuenca, Encarnacion S. C.
    Fry-Smith, Anne
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (02):
  • [25] Certolizumab Pegol Therapy for Rheumatoid Arthritis-Associated Scleritis
    Tlucek, Paul S.
    Stone, Donald U.
    CORNEA, 2012, 31 (01) : 90 - 91
  • [26] Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety
    Mease, Philip J.
    RHEUMATOLOGY, 2011, 50 (02) : 261 - 270
  • [27] Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis
    Rosa, J.
    Sabelli, M.
    Soriano, Enrique R
    Medical Devices: Evidence and Research, 2010, 3 (01) : 25 - 31
  • [28] Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
    Ruiz Garcia, Vicente
    Burls, Amanda
    Cabello, Juan B.
    Vela Casasempere, Paloma
    Bort-Marti, Sylvia
    Bernal, Jose A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (09):
  • [29] Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
    Smolen, Josef S.
    Taylor, Peter C.
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Hashimoto, Motomu
    Cara, Carlos
    Lauwerys, Bernard
    Tilt, Nicola
    Ufuktepe, Baran
    Xavier, Ricardo M.
    Balsa, Alejandro
    Curtis, Jeffrey R.
    Mikuls, Ted R.
    Weinblatt, Michael
    RHEUMATOLOGY, 2024, 63 (11) : 3015 - 3024
  • [30] Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis
    Esposito, Maria
    Carubbi, Francesco
    Giunta, Alessandro
    Alunno, Alessia
    Giacomelli, Roberto
    Fargnoli, Maria Concetta
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (02) : 119 - 128
12345